Chromadex Corp Stock
Chromadex Corp Stock
A loss of -1.490% shows a downward development for Chromadex Corp.
The community is currently still undecided about Chromadex Corp with 1 Buy predictions and 0 Sell predictions.
With a target price of 3 € there is a slightly positive potential of 13.64% for Chromadex Corp compared to the current price of 2.64 €.
Our community identified positive and negative aspects for Chromadex Corp stock for the coming years. 0 users see the criterium "EBIT Margin" as a plus for the Chromadex Corp stock. On the other hand our users think that "EBIT Margin" could be a problem in the future.
Pros and Cons of Chromadex Corp in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Chromadex Corp vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Chromadex Corp | -1.490% | 1.527% | -9.524% | -67.362% | -51.636% | 94.161% | -59.697% |
| Intellia Therapeutics Inc | 3.380% | 4.102% | 11.506% | 21.717% | 36.562% | -69.173% | -91.652% |
| Cardio3 Biosciences S.A. | 3.430% | 1.304% | 5.909% | -36.164% | 72.593% | -55.871% | -93.065% |
| Arbutus Biopharma Corp. | 7.600% | 6.767% | 6.767% | 41.905% | 6.181% | 124.211% | 73.594% |
Comments
ChromaDex Co. (NASDAQ: CDXC) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for CDXC provided by MarketBeat
ChromaDex Co. (NASDAQ: CDXC) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for CDXC provided by MarketBeat
ChromaDex Co. (NASDAQ: CDXC) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for CDXC provided by MarketBeat